Understanding How Insulin Formulations Work: The Pharmacology Behind Clinical Performance

The clinical behaviour of an insulin preparation begins long before it is administered to a patient. Its onset of action, duration, consistency and glucose-lowering profile are determined by the way the insulin molecule has been formulated. Modifications involving crystal formation, protein interactions and molecular engineering allow different preparations to release insulin at different rates, creating distinct pharmacological profiles. 

For veterinarians managing canine diabetes mellitus, understanding these formulation principles provides valuable context for interpreting insulin performance. Appreciating why one insulin acts differently from another helps explain differences in clinical response without assuming that all insulin preparations are interchangeable. 

From Insulin Molecule to Active Hormone 

Canine insulin is produced as preproinsulin, which undergoes several processing steps before becoming the mature hormone. Following removal of the signal peptide and cleavage of the central C-peptide, mature insulin consists of two peptide chains linked by disulphide bonds. 

Although insulin exerts its biological effect as a monomer, individual insulin molecules naturally associate in solution. Monomers combine to form dimers, which can further assemble into hexamers in the presence of zinc ions. These hexamers serve as stable storage forms of insulin, protecting the hormone from degradation until it is released into circulation^1,2. 

The structure of these complexes is not fixed. Insulin hexamers exist in different conformational states, and transitions between these forms influence their stability and the rate at which insulin becomes available after administration¹. These structural characteristics form the basis for many modern insulin formulations. 

Why Zinc and Protamine Matter 

Several intermediate-acting insulin preparations prolong their effect by modifying the physical characteristics of insulin rather than altering the hormone itself. 

Lente insulin achieves this by combining insulin with zinc to produce crystals of different sizes. Smaller crystals dissolve relatively quickly, while larger crystals dissolve more slowly after subcutaneous injection, extending the duration of insulin release³. By combining both crystal populations, lente insulin provides an intermediate duration of activity suitable for long-term management. 

Neutral Protamine Hagedorn (NPH) insulin uses a different strategy. Here, insulin is crystallised with zinc in the presence of protamine, forming complexes that gradually dissociate following injection. As these complexes break down, insulin is slowly released into circulation. Because factors such as crystal characteristics and resuspension can differ between injections; absorption may also vary, contributing to less predictable pharmacokinetics^1,4. 

Protamine zinc insulin (PZI) extends this concept further by incorporating excess protamine together with zinc, producing an even more prolonged insulin effect. While this longer duration may benefit some patients, variability in absorption remains an important characteristic of the formulation¹. 

How Insulin Analogues Extend Their Action 

Long-acting analogue insulins prolong insulin availability through targeted molecular modifications. 

Insulin glargine has an altered isoelectric point that reduces its solubility at physiological pH. After subcutaneous injection, it forms microscopic precipitates that gradually release insulin into circulation. The 300 U/mL formulation creates a more compact depot than the 100 U/mL preparation, slowing insulin release even further^1,5. 

Insulin detemir prolongs activity through the addition of a fatty acid side chain. This modification promotes self-association of insulin molecules at the injection site while also allowing reversible binding to albumin within subcutaneous tissues and the bloodstream, delaying absorption⁶. 

Insulin degludec uses another approach. Following injection, its modified structure allows formation of long multihexamer chains that act as a subcutaneous insulin reservoir. As zinc gradually diffuses away, insulin monomers are slowly released into circulation. Albumin binding further contributes to its prolonged activity^6,7. 

Practical Clinical Insights 

Understanding formulation science helps explain why insulin preparations produce different clinical profiles. 

In practice, veterinarians should recognise that: 

• Insulin formulation influences onset, peak activity and duration of action. 

• Zinc and protamine modify insulin release through controlled crystal dissolution. 

• Molecular modifications can prolong insulin activity without changing its biological function. 

• Different pharmacological strategies produce distinct absorption patterns after subcutaneous administration. 

• Formulations with similar clinical indications may still behave differently because of their underlying pharmaceutical design. 

Conclusion 

The pharmacological behaviour of insulin is determined as much by formulation as by the insulin molecule itself. Manipulating crystal formation, protein interactions, and molecular structure has enabled the development of preparations with markedly different absorption and duration profiles. Understanding these mechanisms provides veterinarians with a stronger foundation for interpreting insulin performance and appreciating why individual formulations exhibit distinct clinical characteristics in dogs. 

References 

1. Shiel RE, Mooney CT. Insulins for the long term management of diabetes mellitus in dogs: a review. Canine medicine and genetics. 2022 Feb 14;9(1):1. https://link.springer.com/content/pdf/10.1186/s40575-022-00114-9.pdf 

2. Mukherjee S, Mondal S, Deshmukh AA, Gopal B, Bagchi B. What gives an insulin hexamer its unique shape and stability? Role of ten confined water molecules. The Journal of Physical Chemistry B. 2018 Feb 8;122(5):1631-7. https://iisc.ac.in/wp-content/uploads/2018/03/JPCB_Insulin_Water_2018-1.pdf 

3. Jarosinski MA, Dhayalan B, Chen YS, Chatterjee D, Varas N, Weiss MA. Structural principles of insulin formulation and analog design: A century of innovation. Molecular Metabolism. 2021 Oct 1;52:101325. https://www.sciencedirect.com/science/article/pii/S2212877821001721 

4. Lucidi P, Porcellati F, Marinelli Andreoli A, Carriero I, Candeloro P, Cioli P, Bolli GB, Fanelli CG. Pharmacokinetics and pharmacodynamics of NPH insulin in type 1 diabetes: the importance of appropriate resuspension before subcutaneous injection. Diabetes Care. 2015 Dec 1;38(12):2204-10. https://www.academia.edu/download/108976354/dc150801.pdf 

5. Becker RH, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 units· mL− 1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units· mL− 1. Diabetes care. 2015 Apr 1;38(4):637-43. https://diabetesjournals.org/care/article-pdf/38/4/637/623200/dc140006.pdf 

6. Heise T, Mathieu C. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes, Obesity and Metabolism. 2017 Jan;19(1):3-12. https://dom-pubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12782 

7. Tambascia MA, Eliaschewitz FG. Degludec: the new ultra-long insulin analogue. Diabetology & metabolic syndrome. 2015 Jun 26;7(1):57. https://link.springer.com/content/pdf/10.1186/s13098-015-0037-0.pdf